T h e family of Ras proteins plays a central role in the regulation of cell growth and integration of regulatory signals which can govern the cell cycle and proliferation. Mutant m s genes (derived from murine sarcoma viruses) were among the first oncogenes described for their ability to transform cells to a cancerous phenotype [l] . Mutations in one of the three genes (H-, N-and K-rus) encoding Ras proteins have been intimately associated with unregulated cell proliferation and are found in an estimated 30% of all human cancers [2] . T h e frequency of i-us mutations appears to depend upon the specific tumour type analysed. For example, an estimated 90% of pancreatic carcinomas contain a mutated oncogenic Ras protein while i a s mutations are rarely found in mammary carcinomas. T h u s an understanding of the physiology of the Ras proteins and development of inhibitors of Ras function may be important in their applications as chemotherapeutic agents in clinical cancer therapy.
T h e function of normal and oncogenic Ras proteins is absolutely dependent on a series of post-translational modifications which promote membrane association. T h e physical association and localization to the plasma membrane is a prerequisite for Ras function and has propelled development of inhibitors to block the oncoprotein's membrane targeting. T h e first and obligatory modification in post-translational processing is S-farnesylation of a cysteine residue near the C-terminus of the protein. T h e precursor to the mature Ras protein contains a cysteine (C) as the fourth residue from the C-terminal amino acid of the protein. This cysteine residue is followed by two amino acids with aliphatic side chains (AA) and ultimately another residue, X. This tetrapeptide motif, referred to as a CAAX box, is the recognition sequence for protein farnesylation by the enzyme protein farnesyltransferase (PFTase).
T h e amino acid in the ' X position is important 
Synthesis of PFTase inhibitors
T h e development of inhibitors o f PFTase has progressed through both screening of natural products and defined chemical compounds and more rational design based on the substrates of the enzyme reaction. Analogues based on either the CAAX peptide substrate or FPP could be developed, but, to be used effectively in humans, the compounds must be stable and permeant to the cell membrane to gain access to the cytosolic transferase.
A number of farnesylphosptior~ic acids have been reported which are purely competitive inhibitors of PFTase rather than substrates in the enzyme reaction [3-51. These compounds lack the pyrophosphate leaving group of FPP, are potent inhibitors of PFTase and are remarkably selective ( > 1000-fold) in their inhibition of PFTase over other isoprerioid-utilizing enzymes 7 \ztiu. T h e ( x -h ydroxyfarne s yl) p hos phon i c acid derivative partially suppresses H-Ras farnesylation in cell culture at micromolar concentrations and was one of the first compounds to display biological activity [6] . Compounds that contain a lipophilic diacid motif or polycarboxylic acids (e.g. chaetomellic acid and zaragozic acid) are a recurring theme in PF'Tase inhibitors that compete with FPP [7, 8] . T h e natural product manurnycin inhibits PFTase competitively with respect to FPP, inhibits the function of farnesylated proteins in yeast, and is efficacious against both K-and N-ria-transformed fibrosarcomas in mouse models of tumorigenesis [9] . In general all these compounds display some selectivity for PFTase iri 7 i t t -o ; however, iri 73i730 the precise effect on other FPP-utilizing enzymes (e.g. squalene synthetase, FPP synthase) is unclear and therefore so are the cellular effects.
Mechanistic and biochemical studies of PFTase have demonstrated that, although the enzyme utilizes polypeptides as substrates in the cell, tetrapeptides contain the essential determinants for enzyme recognition and thus can be ing non-peptide PFTase analogues may also benefit from the recent elucidation of the PF'l'ase-bound conformation of the tetrapeptide inhibitor, CVWM, and a novel pseudopeptide inhibitor by NMR spectroscopy [21, 22] . Both inhibitors were shown to adopt non-ideal reverse-turn conformations most closely approximating a type-I11 p-turn (Figure 2 ). The detailed backbone arid side chain information described may aid in the development of new classes of potent non-peptide PFTase inhibitors.
While the demonstration that inhibition of PFTase reduces the rate of growth of transformed cell lines in tissue culture experiments (cytostatic agents), the dramatic successes obtained in whole animal models has provided an incentive to pursue PFTase inhibitors vigorously.
I I-Ras tumours implanted in immunocompromised mice are sensitive, while the PFTase inhibitors fail to affect cells transformed by Raf, demonstrating that the effects are due to inhibition of the Ras pathway. Similarly the inhibitors are successful in preventing tumour growth in syngeneic mice using human lung cells [23] or human pancreatic adenocarcinoma cells in culture which have mutations in the iityc or pS3 genes in addition to K-ins [24] . T h e response of the human tumour cell lines suggests that PF'l'ase inhibitors may be effective against tuniours with multiple genetic changes.
To date, cell culture studies indicate that PFTase inhibitors would act primarily as cytostatic agents; however, recent studies conducted in transgenic mice that overexpress the v-H-ins oncogene demonstrate that tumour regression can be induced by inhibiting protein farnesylation [25] . Complete regression of 100% of small established tumours and partial regression (partial with respect to the number of respondents and degree of response) of large mammary and salivary tumours was achieved with the isopropyl ester of L-739,750. At a dose of 40 mg of L-744,832/day per kg of body weight, subcutaneously, tumours ranging in size from 50 to 2000 mmj were observed to undergo nearly complete regression within a few weeks of initiation of treatment. Remarkably, mice treated for up to 11 weeks with this compound showed no apparent signs of toxicity to the gastrointestinal tract, bone marrow or retina, all tissues known to contain farnesylated proteins or be dependent upon rapid growth and differentiation of cells. Thus in rodent systems, as in the tissue culture models, the potential for a high therapeutic index is implied.
In order to understand the success of PFTase inhibitors to date and their potential clinical utility, several questions remain to be answered. What mechanisms may normal or transformed cells utilize to compensate for the loss of farnesylation? 'The mechanism by which the related PGGTase-I can recognize the variety of substrates, including K-Ras, has been demonstrated in 7itro [26] . Cross-prenylation may have significant implications and may contribute to the apparent safety of the current inhibitors. T h e long-term consequence of inhibiting PFTase in humans is a prime concern and the rodent models to date are limited in duration and scope. Although the development of resistance is an important unresolved concern, it is promising to note that tumours that re-appear after treatment is stopped (two of three), or fail more traditional doxorubicin therapy (three of five) in the v-H-Ras transgenic mice remain sensitive to the PFTase inhibitor. Future experiments will reveal the answers to these questions and pose more perplexing inquiries while the utility of targeting PFTase for the treatment of cancer is tested.
Introduction
T h e Ras family of GTPases plays a pivotal role in cell growth regulation, differentiation and development. In mammalian cells three genes encode four Ras proteins H, N, KA and KB that are highly homologous [l] . Ras proteins cycle between their GDP (inactive) and G T P (active) forms to relay biological information from incom- T h e most promising are those that were rationally designed to inhibit post-translational steps of Ras that are required for its membrane association and cancer-causing activity.
